AZN Stock Overview
A biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
AstraZeneca PLC Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£65.35 |
| 52 Week High | UK£87.68 |
| 52 Week Low | UK£60.47 |
| Beta | 0.18 |
| 1 Month Change | -0.43% |
| 3 Month Change | -15.28% |
| 1 Year Change | -1.42% |
| 3 Year Change | 13.38% |
| 5 Year Change | 29.56% |
| Change since IPO | 1,196.20% |
Recent News & Updates
Recent updates
AstraZeneca: Strong Growth Potential And Market Volatility Offer Opportunity
Nov 13AstraZeneca: Contrarian Buy After The China Challenge (Rating Upgrade)
Nov 07AstraZeneca: Buy This Big Pharma Stock At A Discount Now
Sep 24AstraZeneca: Dato-DXd Should Still Be Approved In Q4 Despite Underwhelming Data
Sep 12Shareholder Returns
| AZN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -1.8% | -1.6% | -2.4% |
| 1Y | -1.4% | 7.8% | 23.3% |
Return vs Industry: AZN underperformed the US Pharmaceuticals industry which returned 7.8% over the past year.
Return vs Market: AZN underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 3.5% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AZN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AZN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 89,900 | Pascal Soriot | www.astrazeneca.com |
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease.
AstraZeneca PLC Fundamentals Summary
| AZN fundamental statistics | |
|---|---|
| Market cap | US$199.93b |
| Earnings (TTM) | US$6.50b |
| Revenue (TTM) | US$51.21b |
30.8x
P/E Ratio3.9x
P/S RatioIs AZN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AZN income statement (TTM) | |
|---|---|
| Revenue | US$51.21b |
| Cost of Revenue | US$8.91b |
| Gross Profit | US$42.30b |
| Other Expenses | US$35.80b |
| Earnings | US$6.50b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 06, 2025
| Earnings per share (EPS) | 4.19 |
| Gross Margin | 82.61% |
| Net Profit Margin | 12.68% |
| Debt/Equity Ratio | 74.0% |
How did AZN perform over the long term?
See historical performance and comparisonDividends
2.3%
Current Dividend Yield71%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:49 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
AstraZeneca PLC is covered by 80 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Kamla Singh | AlphaValue |
| John Eade | Argus Research Company |